Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Ypsomed Holding stock price, quote, forecast and news

YPSN.SW
CH0019396990
A0B8VP

Price

423.00 CHF
Today +/-
-1.60 CHF
Today %
-0.35 %
P

Ypsomed Holding stock price

CHF
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Ypsomed Holding stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Ypsomed Holding stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Ypsomed Holding stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Ypsomed Holding's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Ypsomed Holding Stock Price History

DateYpsomed Holding Price
9/13/2024423.00 CHF
9/12/2024424.50 CHF
9/11/2024419.50 CHF
9/10/2024422.00 CHF
9/9/2024430.00 CHF
9/6/2024416.00 CHF
9/5/2024421.50 CHF
9/4/2024424.50 CHF
9/3/2024429.00 CHF
9/2/2024424.00 CHF
8/30/2024415.00 CHF
8/29/2024415.00 CHF
8/28/2024408.00 CHF
8/27/2024386.50 CHF
8/26/2024385.00 CHF
8/23/2024406.00 CHF
8/22/2024407.00 CHF
8/21/2024406.00 CHF
8/20/2024408.00 CHF
8/19/2024412.00 CHF

Ypsomed Holding Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Ypsomed Holding, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Ypsomed Holding from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Ypsomed Holding’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Ypsomed Holding. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Ypsomed Holding’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Ypsomed Holding’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Ypsomed Holding’s growth potential.

Ypsomed Holding Revenue, EBIT and net profit per share

DateYpsomed Holding RevenueYpsomed Holding EBITYpsomed Holding Net Income
2030e1.82 B CHF0 CHF0 CHF
2029e1.58 B CHF426.13 M CHF0 CHF
2028e1.34 B CHF365.28 M CHF0 CHF
2027e1.05 B CHF277.54 M CHF209.45 M CHF
2026e853.61 M CHF217.95 M CHF162.59 M CHF
2025e702 M CHF154.21 M CHF111.6 M CHF
2024548.46 M CHF86.22 M CHF78.37 M CHF
2023497.46 M CHF43.2 M CHF51.28 M CHF
2022464.84 M CHF28.58 M CHF23.11 M CHF
2021403.66 M CHF1.47 M CHF5.81 M CHF
2020394.26 M CHF1.99 M CHF11.73 M CHF
2019453.77 M CHF73.34 M CHF60.14 M CHF
2018466.12 M CHF61.07 M CHF52.06 M CHF
2017389.56 M CHF55.3 M CHF46.25 M CHF
2016336.92 M CHF44.44 M CHF35.81 M CHF
2015306.63 M CHF28.55 M CHF19.4 M CHF
2014276.3 M CHF15.7 M CHF13.6 M CHF
2013244.6 M CHF4.8 M CHF1.6 M CHF
2012248.6 M CHF5.1 M CHF8.5 M CHF
2011242.5 M CHF8.2 M CHF5.2 M CHF
2010254 M CHF10.1 M CHF9.4 M CHF
2009272.6 M CHF30.4 M CHF26.2 M CHF
2008287.5 M CHF31 M CHF26.6 M CHF
2007277.5 M CHF2.3 M CHF2.7 M CHF
2006310.6 M CHF62.3 M CHF55.6 M CHF
2005241.8 M CHF47.5 M CHF39.2 M CHF

Ypsomed Holding Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B CHF)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M CHF)EBIT (M CHF)EBIT MARGIN (%)NET INCOME (M CHF)NET INCOME GROWTH (%)DIV. (CHF)DIV. GROWTH (%)SHARES (M)DOCUMENTS
200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
0.10.140.190.240.310.280.290.270.250.240.250.240.280.310.340.390.470.450.390.40.460.50.550.70.851.051.341.581.82
-37.0035.0430.2728.63-10.653.61-5.23-6.62-4.722.48-1.6113.1110.879.8015.7719.79-2.79-13.022.2815.147.1110.2628.1021.5123.3327.3818.2115.15
25.0030.6638.3839.8338.3923.1031.3630.8825.9827.2722.5823.3625.3627.7830.6532.1329.8334.4422.8423.3324.3528.1734.49------
254271961196490846666565770851031251391569094113140189000000
6141747622313010854152844556173112843861542172773654260
6.0010.229.1919.5020.000.7210.8011.033.943.312.021.645.439.1513.1014.1413.0916.110.250.256.038.6515.6921.9425.4426.3327.2426.89-
512113955226269581131935465260115235178111162209000
-140.00-8.33254.5541.03-96.361,200.00--65.38-44.4460.00-87.501,200.0046.1584.2131.4313.0415.38-81.67-54.55360.00121.7452.9442.3145.9529.01---
-----------------------------
-----------------------------
11.211.211.211.211.211.211.211.21212.612.612.612.612.6212.6212.6112.5912.612.612.6112.6513.4213.65000000
-----------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Ypsomed Holding Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Ypsomed Holding is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M CHF)RECEIVABLES (M CHF)OTHER REC. (M CHF)INVENTORIES (M CHF)OTHER CURRENT LIAB. (M CHF)CURRENT ASSETS (M CHF)TANGIBLE ASSETS (M CHF)LONG-T. INVEST. (M CHF)LONG-T. REC. (M CHF)INTANGIBLE ASSETS (M CHF)GOODWILL (M CHF)OTHER NON-CURRENT ASSETS (M CHF)NON-CURRENT ASSETS (M CHF)TOTAL ASSETS (B CHF)LIABILITIESCOMMON STOCK (M CHF)ADDITIONAL PAID-IN CAPITAL (M CHF)RETAINED EARNINGS (M CHF)OTHER EQUITY (M CHF)UNREAL. GAINS/LOSSES (M CHF)EQUITY (M CHF)LIABILITIES (M CHF)PROVISIONS (M CHF)OTHER SHORT-TERM LIAB. (M CHF)SHORT-TERM DEBTS (M CHF)LONG-TERM DEBT PORTION (M CHF)SHORT-TERM REC. (M CHF)LONG-T. LIAB. (M CHF)DEFERRED TAXES (M CHF)OTHER LIAB. (M CHF)LONG-T. LIABILITIES (M CHF)DEBT (M CHF)TOTAL CAPITAL (B CHF)
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                             
1.93.912.6125.6106.966.258.311.38.159.79.616.216.2425.5138.8832.1112.0822.3322.4117.0425.2274.02
16.119.43039.645.433.83030.632.232.224.531.235.345.3452.7163.798.4889.776.2972.6686.9993.34128.03
0.23.59.95.67.26.27.87.15.85.30.20.10.10.090.080.030.160.150.060.070.160.070.07
24.730.737.734.644.137.542.244.246.851.650.156.652.251.7849.148.3259.2852.4156.2963.3668.357.775.29
1.83.63.11.73.717.965.27.313.410.111.310.810.0420.9724.4528.2824.4534.9226.6421.13260.55
44.761.193.3207.1207.3161.6144.398.4100.2107.594.6108.8114.6123.5148.36175.38218.31178.79189.89185.14193.58208.33337.95
70.879.9101.6145.9145.1146.3166.4182.9186.3179.1149.6144.6144.1137.44140.82146.32180.55256.14300.71326.2327.95379.59437.32
00009.19.706.420.122.125.825.425.722.121.0822.6821.9621.238.5710.8510.8510.7310.68
0000000000000000047.3643.480000
0.80.81.61.82.72.415.831.943.349.450.255.161.369.0172.9873.5877.1481.42102.52160.73190.78231.74281.58
00299299299299.1310.1309.7309312.20000000000000
0.81.25.34.72.53.71.82.93.24.57.17.98.89.175.633.862.282.8133.0734.7733.7631.533.87
72.481.9407.5451.4458.4461.2494.1533.8561.9567.3232.7233239.9237.71240.51246.42281.93408.96488.35532.54563.33653.55763.45
0.120.140.50.660.670.620.640.630.660.670.330.340.350.360.390.420.50.590.680.720.760.861.1
                                             
89.899.60.3140.6130.4116.4116.4109.6182.2179179179179178.99178.99178.99178.99178.99178.99178.99178.99193.14193.14
00000000000000000000000
5.812.111.6216.6273.6273.7301.2327.4355.6359.1370.4369.5380.6396.6424.95459.22497.38539.87547.28551.07559.72708.88769.86
0000000000-322.9-322.9-322.9-333.32-332.28-333.33-328.24-333.47-342.02-333.72-346.17-339.52-345.26
00000000000000000000000
95.6111.711.9357.2404390.1417.6437537.8538.1226.5225.6236.7242.27271.67304.89348.14385.4384.25396.34392.54562.5617.74
3.69.516.841.623.711.416.915.113.313.113.516.715.915.4819.9721.9631.9219.3524.0434.5517.3919.6230.88
7.2710.315.816.214.216.816.915.220.612.713.416.320.2423.6829.4132.7231.7626.6829.2836.7944.2848.95
1.62.56.187.914.914.311.49.4178.26.88.38.922.6824.6428.8224.7842.2826.0426.1638.08104.39
4.24.2000000405056.564.562.556342749112183182.5157157256
00000000000000500000000
16.623.233.265.447.840.54843.477.9100.790.9101.4103100.63105.33103.01142.45187.88276272.38237.34258.99440.22
00439.2218.120018016014035.224.516.821.721.115.4710.0110.0610101032.511000
2.33.63.93.94.14.64.13.733.30.60.41.11.772.893.972.92.92.172.542.782.513.22
2.74.512.613.99.87.68.58.18.28111.22.712.82.973.358.1612.4114.8814.2538.0540.22
58.1455.7235.9213.9192.2172.6151.846.435.818.423.123.419.9515.711716.2421.0624.5849.92127.0340.5643.44
21.631.3488.9301.3261.7232.7220.6195.2124.3136.5109.3124.5126.4120.57121.04120.01158.7208.94300.58322.3364.37299.55483.66
0.120.140.50.660.670.620.640.630.660.670.340.350.360.360.390.420.510.590.680.720.760.861.1
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Ypsomed Holding provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Ypsomed Holding's financial health and stability.

Assets

Ypsomed Holding's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Ypsomed Holding must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Ypsomed Holding after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Ypsomed Holding's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M CHF)DEPRECIATION (M CHF)DEFERRED TAXES (M CHF)CHANGES IN WORKING CAPITAL (M CHF)NON-CASH ITEM (M CHF)PAID INTEREST (M CHF)PAID TAXES (M CHF)NET CASH FLOW FROM OPERATING ACTIVITIES (M CHF)CAPITAL EXPENDITURES (M CHF)CASH FLOW FROM INVESTING ACTIVITIES (M CHF)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M CHF)INTEREST INCOME AND EXPENSES (M CHF)NET DEBT CHANGE (M CHF)NET CHANGE IN EQUITY (M CHF)CASH FLOW FROM FINANCING ACTIVITIES (M CHF)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M CHF)TOTAL DIVIDENDS PAID (M CHF)NET CHANGE IN CASH FLOW (M CHF)FREE CASH FLOW (M CHF)SHARE-BASED COMPENSATION (M CHF)
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
51211395522626117811319354652601152351
11133021262524262725262524262730344452566878
0000000000000000000000
-12-6-1632-19516-8-14-40-103-116-4-30013-12-710
1111-5-124-21-300672-2-44-29361-11
0021110000000000000000
1024662201000000000000
62026945732704822293115414176755359498585129
-18-22-38-72-42-37-53-59-46-26-15-26-30-30-36-38-67-129-118-126-127-169
-18-22-38-66-41-19-52-49-43-27-19-26-30-26-35-38-65-128-115-106-125-122
0006018192-1-30040010219147
0000000000000000000000
-1017-19111-20-20-20190-313-2-11-22-122263712252-25
0002061-200800001-21-1006034
1241714-6-38-20-2820-4-610-4-14-31-234496826381
14400-9-1000-1000000034100
0000-10-140-6-7-3-2-2-2-3-7-12-16-17-6-2-14-8
015439-24-2-290-34060913-6-2015-28
-12.24-2.52-11.4722.3115.12-5.5616.81-11.06-23.93.2815.13-11.2410.5710.8940.4936.9-13.82-69.19-69.64-40.75-41.72-39.64
0000000000000000000000

Ypsomed Holding stock margins

The Ypsomed Holding margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ypsomed Holding. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ypsomed Holding.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Ypsomed Holding's sales revenue. A higher gross margin percentage indicates that the Ypsomed Holding retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Ypsomed Holding's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Ypsomed Holding's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Ypsomed Holding's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Ypsomed Holding. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Ypsomed Holding's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Ypsomed Holding Margin History

Ypsomed Holding Gross marginYpsomed Holding Profit marginYpsomed Holding EBIT marginYpsomed Holding Profit margin
2030e34.47 %0 %0 %
2029e34.47 %26.9 %0 %
2028e34.47 %27.24 %0 %
2027e34.47 %26.38 %19.91 %
2026e34.47 %25.53 %19.05 %
2025e34.47 %21.97 %15.9 %
202434.47 %15.72 %14.29 %
202328.26 %8.68 %10.31 %
202224.49 %6.15 %4.97 %
202123.49 %0.36 %1.44 %
202023.07 %0.5 %2.98 %
201934.47 %16.16 %13.25 %
201830 %13.1 %11.17 %
201732.21 %14.2 %11.87 %
201630.63 %13.19 %10.63 %
201528 %9.31 %6.33 %
201425.52 %5.68 %4.92 %
201323.34 %1.96 %0.65 %
201222.69 %2.05 %3.42 %
201127.51 %3.38 %2.14 %
201026.14 %3.98 %3.7 %
200930.81 %11.15 %9.61 %
200831.37 %10.78 %9.25 %
200723.14 %0.83 %0.97 %
200638.38 %20.06 %17.9 %
200540.07 %19.64 %16.21 %

Ypsomed Holding Stock Sales Revenue, EBIT, Earnings per Share

The Ypsomed Holding earnings per share therefore indicates how much revenue Ypsomed Holding has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Ypsomed Holding earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ypsomed Holding's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ypsomed Holding’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ypsomed Holding's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Ypsomed Holding Revenue, EBIT and net profit per share

DateYpsomed Holding Sales per ShareYpsomed Holding EBIT per shareYpsomed Holding Earnings per Share
2030e133.88 CHF0 CHF0 CHF
2029e116.2 CHF0 CHF0 CHF
2028e98.37 CHF0 CHF0 CHF
2027e77.17 CHF0 CHF15.36 CHF
2026e62.62 CHF0 CHF11.93 CHF
2025e51.5 CHF0 CHF8.19 CHF
202440.18 CHF6.32 CHF5.74 CHF
202337.07 CHF3.22 CHF3.82 CHF
202236.76 CHF2.26 CHF1.83 CHF
202132.01 CHF0.12 CHF0.46 CHF
202031.28 CHF0.16 CHF0.93 CHF
201936 CHF5.82 CHF4.77 CHF
201837.03 CHF4.85 CHF4.14 CHF
201730.88 CHF4.38 CHF3.67 CHF
201626.69 CHF3.52 CHF2.84 CHF
201524.29 CHF2.26 CHF1.54 CHF
201421.93 CHF1.25 CHF1.08 CHF
201319.41 CHF0.38 CHF0.13 CHF
201219.73 CHF0.4 CHF0.67 CHF
201119.25 CHF0.65 CHF0.41 CHF
201021.17 CHF0.84 CHF0.78 CHF
200924.34 CHF2.71 CHF2.34 CHF
200825.67 CHF2.77 CHF2.38 CHF
200724.78 CHF0.21 CHF0.24 CHF
200627.73 CHF5.56 CHF4.96 CHF
200521.59 CHF4.24 CHF3.5 CHF

Ypsomed Holding business model

Ypsomed Holding AG is a Swiss company specialized in the development and production of medical products. It started in the 1980s when the founder, Willy Michel, established his own company focusing on the production of insulin pens. Today, it has become one of the largest providers of injector systems in Europe. Ypsomed's business model is based on focusing on niche products in medical technology and developing innovative solutions for specific medical problems. It also collaborates closely with leading clinics, research institutions, and other partners to develop new products and improve existing technologies. Ypsomed is divided into different business divisions. One of the largest divisions is Diabetes Care, specializing in the development and production of insulin pens and pumps. Ypsomed is a significant supplier of devices and accessories for some of the world's largest pharmaceutical companies. Another important division of Ypsomed is SelfCare, focused on the development and production of medication delivery systems for self-medication by patients. The offerings range from pen systems to auto-injectors, inhalers, and nasal spray systems. Ypsomed also offers a range of other products, including infection control systems, injection systems for veterinary medicine, and specialty products for wound care. In addition to its products, Ypsomed stands out for its focus on research and development. The company regularly invests in new technologies to find better solutions for medical problems and works closely with leading clinics and research institutions worldwide. Overall, Ypsomed is a leading provider of medical products and solutions for specific medical problems. The company operates in more than 80 countries and has gained a reputation as an innovative partner in the medical technology industry. Ypsomed Holding is one of the most popular companies on Eulerpool.com.

Ypsomed Holding SWOT Analysis

Strengths

Ypsomed Holding AG has several strengths that contribute to its success in the market. These include:

  • Strong market presence with a wide range of innovative medical devices
  • Established brand reputation for quality and reliability
  • Extensive distribution network and partnerships with healthcare providers
  • Technological expertise in designing and manufacturing medical devices
  • Robust financial position and healthy revenue growth

However, Ypsomed Holding AG also faces certain weaknesses that need to be addressed for sustained success:

  • Relatively small market share compared to larger competitors
  • Dependence on a limited number of key suppliers for critical components
  • Higher production costs due to smaller scale of operations
  • Limited geographical presence in certain markets
  • Dependency on regulatory approvals for new product launches

Ypsomed Holding AG has several opportunities to further expand and grow its business:

  • Increasing demand for self-injection and infusion systems in the healthcare industry
  • Growing elderly population globally, increasing the need for medical devices
  • Expanding into emerging markets with rising healthcare expenditure
  • Collaborating with pharmaceutical companies for product development and distribution
  • Technological advancements to improve user experience and device functionality

Ypsomed Holding AG should be mindful of the following threats in the market:

  • Intense competition from larger medical device manufacturers
  • Increasingly stringent regulations and compliance requirements
  • Potential disruptions in the supply chain due to global events or economic factors
  • Price pressures from healthcare providers and payers
  • Rapid technological advancements, leading to potential obsolescence of existing products

Weaknesses

However, Ypsomed Holding AG also faces certain weaknesses that need to be addressed for sustained success:

  • Relatively small market share compared to larger competitors
  • Dependence on a limited number of key suppliers for critical components
  • Higher production costs due to smaller scale of operations
  • Limited geographical presence in certain markets
  • Dependency on regulatory approvals for new product launches

Ypsomed Holding AG has several opportunities to further expand and grow its business:

  • Increasing demand for self-injection and infusion systems in the healthcare industry
  • Growing elderly population globally, increasing the need for medical devices
  • Expanding into emerging markets with rising healthcare expenditure
  • Collaborating with pharmaceutical companies for product development and distribution
  • Technological advancements to improve user experience and device functionality

Ypsomed Holding AG should be mindful of the following threats in the market:

  • Intense competition from larger medical device manufacturers
  • Increasingly stringent regulations and compliance requirements
  • Potential disruptions in the supply chain due to global events or economic factors
  • Price pressures from healthcare providers and payers
  • Rapid technological advancements, leading to potential obsolescence of existing products

Opportunities

Ypsomed Holding AG has several opportunities to further expand and grow its business:

  • Increasing demand for self-injection and infusion systems in the healthcare industry
  • Growing elderly population globally, increasing the need for medical devices
  • Expanding into emerging markets with rising healthcare expenditure
  • Collaborating with pharmaceutical companies for product development and distribution
  • Technological advancements to improve user experience and device functionality

Ypsomed Holding AG should be mindful of the following threats in the market:

  • Intense competition from larger medical device manufacturers
  • Increasingly stringent regulations and compliance requirements
  • Potential disruptions in the supply chain due to global events or economic factors
  • Price pressures from healthcare providers and payers
  • Rapid technological advancements, leading to potential obsolescence of existing products

Threats

Ypsomed Holding AG should be mindful of the following threats in the market:

  • Intense competition from larger medical device manufacturers
  • Increasingly stringent regulations and compliance requirements
  • Potential disruptions in the supply chain due to global events or economic factors
  • Price pressures from healthcare providers and payers
  • Rapid technological advancements, leading to potential obsolescence of existing products

Ypsomed Holding Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Ypsomed Holding historical P/E ratio, EBIT, and P/S ratio.

Ypsomed Holding shares outstanding

The number of shares was Ypsomed Holding in 2023 — This indicates how many shares 13.419 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Ypsomed Holding earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ypsomed Holding's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ypsomed Holding’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ypsomed Holding's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Ypsomed Holding dividend history and estimates

In 2023, Ypsomed Holding paid a dividend amounting to 0.65 CHF. Dividend means that Ypsomed Holding distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Ypsomed Holding provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Ypsomed Holding’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Ypsomed Holding's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Ypsomed Holding Dividend History

DateYpsomed Holding Dividend
2030e1.03 CHF
2029e1.03 CHF
2028e1.03 CHF
2027e1.03 CHF
2026e1.03 CHF
2025e1.03 CHF
20241 CHF
20230.65 CHF
20220.3 CHF
20210.58 CHF
20200.1 CHF
20190.55 CHF
20181.4 CHF
20171.3 CHF
20161 CHF
20150.6 CHF
20140.3 CHF
20130.2 CHF
20120.2 CHF
20110.2 CHF
20100.25 CHF
20090.6 CHF
20080.6 CHF
20061.25 CHF
20050.89 CHF

Ypsomed Holding dividend payout ratio

In 2023, Ypsomed Holding had a payout ratio of 51.01%. The payout ratio indicates the percentage of the company's profits that Ypsomed Holding distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Ypsomed Holding represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Ypsomed Holding could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Ypsomed Holding's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Ypsomed Holding Payout Ratio History

DateYpsomed Holding Payout ratio
2030e52.2 %
2029e52.43 %
2028e50.31 %
2027e53.84 %
2026e53.14 %
2025e43.96 %
202464.44 %
202351.01 %
202216.42 %
2021125.88 %
202010.74 %
201911.53 %
201833.85 %
201735.46 %
201635.25 %
201539.06 %
201427.78 %
2013153.85 %
201229.85 %
201148.78 %
201031.65 %
200925.75 %
200825.32 %
200751.01 %
200625.25 %
200525.49 %
Unfortunately, there are currently no price targets and forecasts available for Ypsomed Holding.

Eulerpool ESG Scorecard© for the Ypsomed Holding stock

Eulerpool World ESG Rating (EESG©)

73/ 100

🌱 Environment

95

👫 Social

79

🏛️ Governance

44

Environment

Scope 1 - Direct Emissions
2,557
Scope 2 - Indirect emissions from purchased energy
1
Scope 3 - Indirect emissions within the value chain
84,867
Total CO₂ emissions
2,558
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
✅
Environmentally friendly packaging
✅
Hazardous substances
✅
Fuel consumption and efficiency
✅
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Ypsomed Holding list of shareholders

%
Name
Stocks
Change
Date
73.88611 % Family (Michel)10,072,139747,2273/31/2023
1.24019 % Capital Research Global Investors169,062132,9963/31/2024
1.04658 % Zürcher Kantonalbank (Asset Management)142,6691,3552/29/2024
0.99401 % Premier Asset Management Ltd135,503-3,22112/31/2023
0.85285 % GAM Investment Management (Switzerland) AG116,26175512/31/2023
0.73434 % The Vanguard Group, Inc.100,105-1,5273/31/2024
0.73325 % Norges Bank Investment Management (NBIM)99,957-3,19412/31/2023
0.66636 % VV Vermögensverwaltung AG90,838721/31/2024
0.56120 % UBS Asset Management (Switzerland)76,5021,9033/31/2024
0.50621 % Bank Vontobel AG (Private Banking)69,00712,50712/31/2023
1
2
3
4
5
...
10

Ypsomed Holding Executives and Management Board

Mr. Simon Michel46
Ypsomed Holding Chief Executive Officer, Executive Director, Member of the Executive Board (since 2008)
Compensation 1.14 M CHF
Mr. Gilbert Achermann59
Ypsomed Holding Non-Executive Chairman of the Board
Compensation 222,000 CHF
Dr. Martin Muenchbach53
Ypsomed Holding Non-Executive Director
Compensation 133,200 CHF
Ms. Betuel Unaran47
Ypsomed Holding Non-Executive Director
Compensation 133,200 CHF
Mr. Paul Fonteyne62
Ypsomed Holding Non-Executive Director
Compensation 123,500 CHF
1
2
3

Most common questions regarding Ypsomed Holding

What values and corporate philosophy does Ypsomed Holding represent?

Ypsomed Holding AG represents a set of core values and a strong corporate philosophy. The company is dedicated to innovation, quality, and patient-centric solutions in the field of medical devices and self-medication systems. Ypsomed prioritizes customer satisfaction through the development of user-friendly and technologically advanced products. With a focus on sustainability, Ypsomed aims to reduce environmental impact throughout its operations. The company fosters a culture of close collaboration, teamwork, and integrity, promoting transparency and trust among its employees and stakeholders. Ypsomed Holding AG's commitment to excellence, social responsibility, and continuous improvement underpins its position as a leading player in the healthcare industry.

In which countries and regions is Ypsomed Holding primarily present?

Ypsomed Holding AG is primarily present in various countries and regions. This prominent company has a global presence, with operations spanning across Europe, Asia, and the Americas. In Europe, Ypsomed Holding AG has a significant presence in countries like Switzerland, Germany, France, Italy, and the United Kingdom. Additionally, it has established a strong foothold in Asian markets, including Japan, China, India, and South Korea. Furthermore, Ypsomed Holding AG also maintains a presence in the Americas, particularly in the United States and Canada. With its extensive international reach, Ypsomed Holding AG is renowned for its wide geographical distribution and successful market penetration.

What significant milestones has the company Ypsomed Holding achieved?

Ypsomed Holding AG, a reputable medical technology company, has achieved numerous significant milestones throughout its history. Some notable achievements include the development and launch of its flagship product, the mylife™ Diabetescare range, which revolutionized insulin pump therapy. Ypsomed also successfully partnered with leading pharmaceutical companies to develop innovative drug delivery systems. Furthermore, the company received regulatory approvals from various health authorities worldwide, expanding its market reach. Ypsomed Holding AG's continuous commitment to research and innovation has led to the introduction of cutting-edge medical devices that empower patients and healthcare professionals alike.

What is the history and background of the company Ypsomed Holding?

Ypsomed Holding AG is a Swiss company specializing in the development and manufacture of innovative injection and infusion systems. Established in 2003, Ypsomed has a rich history of more than 30 years, as it originated from Disetronic, a company established in 1984. Ypsomed focuses on providing self-care solutions for diabetes, which include self-injection pens, autoinjectors, and infusion systems. The company has a strong commitment to enhancing the quality of life for patients and continuously strives to develop user-friendly and reliable medical devices. Ypsomed Holding AG has a global presence and collaborates with various partners to deliver cutting-edge healthcare solutions worldwide.

Who are the main competitors of Ypsomed Holding in the market?

The main competitors of Ypsomed Holding AG in the market include Johnson & Johnson, Medtronic, Becton Dickinson, and Roche Holding AG.

In which industries is Ypsomed Holding primarily active?

Ypsomed Holding AG is primarily active in the healthcare industry.

What is the business model of Ypsomed Holding?

The business model of Ypsomed Holding AG revolves around the production and supply of innovative and high-quality injection and infusion systems for self-medication. Ypsomed specializes in developing and manufacturing pen needles, autoinjectors, and infusion systems for the treatment of diabetes, Parkinson's disease, and other medical conditions. The company's business model focuses on meeting the needs of patients, healthcare professionals, and pharmaceutical companies by providing user-friendly and reliable self-medication solutions. Ypsomed Holding AG has built a strong reputation in the healthcare industry for its commitment to innovation, quality, and patient-centric approach.

What is the P/E ratio of Ypsomed Holding 2024?

The Ypsomed Holding P/E ratio is 73.67.

What is the P/S ratio of Ypsomed Holding 2024?

The Ypsomed Holding P/S ratio is 10.53.

What is the AlleAktien quality score of Ypsomed Holding?

The AlleAktien quality score for Ypsomed Holding is 7/10.

What is the revenue of Ypsomed Holding 2024?

The Ypsomed Holding revenue is 548.46 M CHF.

How high is the profit of Ypsomed Holding 2024?

The Ypsomed Holding profit is 78.37 M CHF.

What is the business model of Ypsomed Holding

The company Ypsomed Holding AG is a leading company in the manufacture and distribution of injection and infusion systems. Ypsomed's business model is based on the production and sale of products for self-medication and medication administration. The main focus is on the easy handling of the products and the resulting improvement in patients' quality of life. Ypsomed is divided into several divisions that focus on different products and areas of the company. The main divisions are: 1. Diabetes Care Ypsomed is a major manufacturer of diabetes treatment products. In this area, the company offers both insulin pens and insulin pumps. The most well-known products include the insulin pen product family mylife™, the pod-based insulin pump family YpsoPump®, and the web-based data management tool Ypsomed Smart Services™. 2. Pharma Supply In the Pharma Supply division, Ypsomed offers individual solutions for medication administration. This includes pens for other indications, such as growth hormone deficiency or psoriatic arthritis, as well as injection and infusion solutions. 3. Contract Manufacturing In addition, the company offers contract manufacturing of injection and infusion systems for third-party customers. Ypsomed works closely with pharmaceutical companies to produce individual solutions for their products. Ypsomed's business model is based on an integrated approach, covering the entire value chain from product development to distribution and service. This means that Ypsomed is able to quickly bring innovative products to market and offer generic products at competitive prices through production. Through distribution via wholesale, distributors, and direct sales, Ypsomed reaches a wide range of customers and patients worldwide. A key element of Ypsomed's business model is close cooperation with healthcare providers and customers who directly supply the products to end consumers. This ensures that market needs are identified early and implementation strategies are developed. In summary, Ypsomed's business model offers patients, pharmaceutical companies, and healthcare providers a wide range of injection and infusion systems for safe and easy use in everyday life. Ypsomed focuses on quality, innovation, and partnerships. Ypsomed aims to maintain its leadership in self-medication innovation and be an important partner for pharmaceutical companies and healthcare institutions worldwide. With this approach, Ypsomed aims for further growth and sustainable development.

What is the Ypsomed Holding dividend?

Ypsomed Holding pays a dividend of 0.3 CHF distributed over payouts per year.

How often does Ypsomed Holding pay dividends?

The dividend cannot currently be calculated for Ypsomed Holding or the company does not pay out a dividend.

What is the Ypsomed Holding ISIN?

The ISIN of Ypsomed Holding is CH0019396990.

What is the Ypsomed Holding WKN?

The WKN of Ypsomed Holding is A0B8VP.

What is the Ypsomed Holding ticker?

The ticker of Ypsomed Holding is YPSN.SW.

How much dividend does Ypsomed Holding pay?

Over the past 12 months, Ypsomed Holding paid a dividend of 1 CHF . This corresponds to a dividend yield of about 0.24 %. For the coming 12 months, Ypsomed Holding is expected to pay a dividend of 1.03 CHF.

What is the dividend yield of Ypsomed Holding?

The current dividend yield of Ypsomed Holding is 0.24 %.

When does Ypsomed Holding pay dividends?

Ypsomed Holding pays a quarterly dividend. This is distributed in the months of August, August, August, August.

How secure is the dividend of Ypsomed Holding?

Ypsomed Holding paid dividends every year for the past 0 years.

What is the dividend of Ypsomed Holding?

For the upcoming 12 months, dividends amounting to 1.03 CHF are expected. This corresponds to a dividend yield of 0.24 %.

In which sector is Ypsomed Holding located?

Ypsomed Holding is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ypsomed Holding kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ypsomed Holding from 7/3/2024 amounting to 1 CHF, you needed to have the stock in your portfolio before the ex-date on 7/1/2024.

When did Ypsomed Holding pay the last dividend?

The last dividend was paid out on 7/3/2024.

What was the dividend of Ypsomed Holding in the year 2023?

In the year 2023, Ypsomed Holding distributed 0.65 CHF as dividends.

In which currency does Ypsomed Holding pay out the dividend?

The dividends of Ypsomed Holding are distributed in CHF.

All fundamentals about Ypsomed Holding

Our stock analysis for Ypsomed Holding Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ypsomed Holding Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.